Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherClinical Investigations

Potential of 99mTc-MIBI for Detecting Bone Marrow Metastases

Shigetoshi Wakasugi, Atushi Noguti, Toshizou Katuda, Terumi Hashizume and Yoshihisa Hasegawa
Journal of Nuclear Medicine May 2002, 43 (5) 596-602;
Shigetoshi Wakasugi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atushi Noguti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshizou Katuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terumi Hashizume
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshihisa Hasegawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Classification of 99mTc-MIBI activity patterns. (A) No detectable activity in patient with breast cancer was confirmed by lack of abnormal MRI findings. (B) Homogeneous mild activity in patient with lung cancer was confirmed by lack of abnormal MRI findings. (C) Clearly visualized focal activity in patient with malignant lymphoma (non-Hodgkin’s) was confirmed by abnormal MRI findings and bone marrow cytology from puncture sites on each anterior iliac crest. Clearly visualized activity of 99mTc-MIBI was interpreted as abnormal.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Normal 99mTc-MIBI skeletal images of woman with hypertension with no evidence of cancer. Homogeneous mild activity was found in thoracic spine, ribs, and lumbar spine; no detectable activity was evident in femur.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Patient with breast cancer. (A) Initial 99mTc-HMDP scans show no bone metastases. (B) 99mTc-MIBI scans show multiple lesions in thoracic spine, bilateral proximal femur, and right pubic bone. Findings were confirmed 1 mo later by MRI. (C) Multiple intense accumulations of 99mTc-HMDP appeared 4 mo later on whole-body scans. (D) Further 99mTc-MIBI scans (second set) show increased accumulations in thoracic spine, bilateral proximal femur, and left lung metastatic lesion. 99mTc-HMDP accumulations in more extensive sites, including bilateral proximal femur, appeared 2 mo after obtaining second set of 99mTc-HMDP scans.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Patient with lung cancer. (A) 99mTc-HMDP scans show no definite bone metastases, although anterior pelvis image could not be obtained. (B) 99mTc-MIBI scans show increased uptake in multiple regions of ribs, in thoracic and lumbar spine, and in right lung tumor and also show irregular-shaped uptake in bilateral proximal femur in anterior pelvis image. MRI showed multiple metastases in thoracic spine, and bone marrow cytology from puncture sites on sternum showed many lung cancer cells.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Patient with colon cancer. (A) 99mTc-HMDP scans show no metastases in thoracic spine. (B) Corresponding 99mTc-MIBI scans reveal diffuse intense uptake in thoracic spine. Bone marrow cytology from puncture sites on each anterior iliac crest indicated positive findings.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Patient with prostate cancer. (A) 99mTc-HMDP scans show multiple intense accumulations in cervical spine, thoracic spine, lumbar spine, skull, and ribs. (B) In contrast, 99mTc-MIBI scans do not show any abnormalities.

Tables

  • Figures
    • View popup
    TABLE 1

    Comparison of Detectability of Bone Metastases Between 99mTc-HMDP and 99mTc-MIBI Scans in Relation to Skeletal Sites

    SiteNo. of metastases99mTc-HMDP(+), 99mTc-MIBI(−)99mTc-HMDP(−), 99mTc-MIBI(+)99mTc-HMDP(+), 99mTc-MIBI(+)99mTc-HMDP(+)*99mTc-MIBI(+)*99mTc-HMDP vs. 99mTc-MIBI
    Rib5715123045 (78.9)42 (73.7)NS
    Thoracic spine33861927 (81.8)25 (75.8)NS
    Lumbar spine23941019 (82.6)14 (60.9)NS
    Sternum18041414 (77.8)18 (100)NS
    Pelvis6212113951 (82.3)50 (80.6)NS
    Humerus221111011 (50.0)21 (95.5)P < 0.005
    Femur981633435 (35.7)97 (99.0)P < 0.005
    Other21451216 (76.2)17 (81.0)NS
    Total33450116168218 (65.3)284 (85.0)P < 0.005
    • ↵* Value in parentheses is percentage.

    • 99mTc-HMDP(+) = 99mTc-HMDP positive; 99mTc-HMDP(−) = 99mTc-HMDP negative; 99mTc-MIBI(+) = 99mTc-MIBI positive; 99mTc-MIBI(−) = 99mTc-MIBI negative; NS = not significant.

    • View popup
    TABLE 2

    Comparison of Detectability of Bone Metastases Between 99mTc-HMDP and 99mTc-MIBI Scans in Relation to Underlying Primary Malignancy

    Primary malignancyNo. of metastases99mTc-HMDP(+), 99mTc-MIBI(−)99mTc-HMDP(−), 99mTc-MIBI(+)99mTc-HMDP(+), 99mTc-MIBI(+)99mTc-HMDP(+)*99mTc-MIBI(+)*99mTc-HMDP vs. 99mTc-MIBI
    Breast cancer6910273242 (60.9)59 (85.5)P < 0.005
    Lung cancer6817203148 (70.6)51 (75.0)NS
    Prostate cancer38942534 (89.5)29 (76.3)NS
    Myeloma300131717 (56.7)30 (100)P < 0.005
    Hepatoma210111010 (47.6)21 (100)P < 0.005
    Gastric cancer21431418 (85.7)17 (81.0)NS
    Bladder cancer17021515 (88.2)17 (100)NS
    Renal cancer114437 (63.6)7 (63.6)NS
    Colon cancer112368 (72.7)9 (81.8)NS
    • ↵* Value in parentheses is percentage.

    • 99mTc-HMDP(+) = 99mTc-HMDP positive; 99mTc-HMDP(−) = 99mTc-HMDP negative; 99mTc-MIBI(+) = 99mTc-MIBI positive; 99mTc-MIBI(−) = 99mTc-MIBI negative; NS = not significant.

    • View popup
    TABLE 3

    Comparison of Detectability of Bone Metastases Between 99mTc-HMDP and 99mTc-MIBI Scans in Regions of Femur and Humerus

    Primary malignancyNo. of metastases99mTc-HMDP(+), 99mTc-MIBI(−)99mTc-HMDP(−), 99mTc-MIBI(+)99mTc-HMDP(+), 99mTc-MIBI(+)99mTc-HMDP(+)*99mTc-MIBI(+)*99mTc-HMDP vs. 99mTc-MIBI
    Breast cancer2101477 (33.3)21 (100)P < 0.005
    Lung cancer29291820 (69.0)27 (93.1)P < 0.05
    Prostate cancer110388 (72.7)11 (100)NS
    Myeloma110566 (54.5)11 (100)P < 0.05
    Hepatoma1201022 (16.7)12 (100)P < 0.005
    Gastric cancer40311 (25.0)4 (100)NS
    Bladder cancer20022 (100)2 (100)NS
    Renal cancer50411 (20.0)5 (100)NS
    Colon cancer303003 (100)NS
    • ↵* Value in parentheses is percentage.

    • 99mTc-HMDP(+) = 99mTc-HMDP positive; 99mTc-HMDP(−) = 99mTc-HMDP negative; 99mTc-MIBI(+) = 99mTc-MIBI positive; 99mTc-MIBI(−) = 99mTc-MIBI negative; NS = not significant.

    • View popup
    TABLE 4

    Comparison of Detectability of Bone Metastases Between 99mTc-HMDP and 99mTc-MIBI Scans in Regions Other Than Femur and Humerus

    Primary malignancyNo. of metastases99mTc-HMDP(+), 99mTc-MIBI(−)99mTc-HMDP(−), 99mTc-MIBI(+)99mTc-HMDP(+), 99mTc-MIBI(+)99mTc-HMDP(+)*99mTc-MIBI(+)*99mTc-HMDP vs. 99mTc-MIBI
    Breast cancer4810132535 (72.9)38 (79.2)NS
    Lung cancer391391730 (76.9)26 (66.7)NS
    Prostate cancer27911726 (96.3)18 (66.7)P < 0.025
    Myeloma19071212 (63.2)19 (100)P < 0.025
    Hepatoma90188 (88.9)9 (100)NS
    Gastric cancer17401317 (100)13 (76.5)NS
    Bladder cancer15021313 (86.7)15 (100)NS
    Renal cancer64026 (100)2 (33.3)NS
    Colon cancer82068 (100)6 (75.0)NS
    • ↵* Value in parentheses is percentage.

    • 99mTc-HMDP(+) = 99mTc-HMDP positive; 99mTc-HMDP(−) = 99mTc-HMDP negative; 99mTc-MIBI(+) = 99mTc-MIBI positive; 99mTc-MIBI(−) = 99mTc-MIBI negative; NS = not significant.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 43, Issue 5
May 1, 2002
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Potential of 99mTc-MIBI for Detecting Bone Marrow Metastases
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Potential of 99mTc-MIBI for Detecting Bone Marrow Metastases
Shigetoshi Wakasugi, Atushi Noguti, Toshizou Katuda, Terumi Hashizume, Yoshihisa Hasegawa
Journal of Nuclear Medicine May 2002, 43 (5) 596-602;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Potential of 99mTc-MIBI for Detecting Bone Marrow Metastases
Shigetoshi Wakasugi, Atushi Noguti, Toshizou Katuda, Terumi Hashizume, Yoshihisa Hasegawa
Journal of Nuclear Medicine May 2002, 43 (5) 596-602;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Severity of Bone Marrow Involvement in Patients with Gaucher's Disease Evaluated by Scintigraphy with 99mTc-Sestamibi
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire